Avacta Group, the developer of Affimer biotherapeutics and reagents, has begun work with the UK government’s CONDOR programme to evaluate and validate the high-throughput COVID-19 bead-assisted mass spectrometry (BAMS) assay developed with Adeptrix.
EKF Diagnostics has added a novel viral transport media for the safe sample handling and testing of multiple infectious diseases from a single swab to its product range. PrimeStore MTM is a collection device that deactivates viruses.
Bio-Rad Laboratories is accelerating production of its Platelia SARS-CoV-2 Total Ab test, a blood-based immunoassay kit to help determine if an individual has developed antibodies to SARS-CoV-2, the virus associated with COVID-19 disease.
The UK must prepare now for a potential new wave of coronavirus infections this winter that could be more serious than the first, says a new report from the Academy of Medical Sciences.
Avacta Group, the developer of Affimer biotherapeutics and reagents, is collaborating with Integumen to evaluate recently generated Affimer reagents that bind the SARS-CoV-2 spike protein for the detection of the coronavirus in waste water.
Xebios Diagnostics manufactures high-quality, ready-to-use culture media for microbiological diagnostic applications, and is using DOSE IT to aliquot viral transport medium (VTM) into sterile screw-capped tubes to meet market demand.
Randox Laboratories has installed an RX modena in a COVID-19 hospital in India, at the Netaji Subhash Chandra Bose Medical College in Madhya Pradesh state.
Scientists from PrecisionLife have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyse the genomes of 929 patients who had a severe response to SARS-CoV-2.
Una Health, a distributor of in vitro diagnostics (IVDs), and Fortress Diagnostics, a provider of IVDs, are partnering with the Department of Health & Social Care in the Real Time Assessment of Community Transmission (REACT) study into COVID-19.
HORIBA UK, Medical has published a white paper entitled ‘COVID-19 screening, prognosis and severity assessment with biomarkers for management of patients’. The paper provides a review of biomarkers that help in the assessment of COVID-19 severity.
Avacta Group has announced that the first Affimer-based rapid test strips to detect SARS-COV-2 spike protein have been evaluated by Avacta’s partners at Cytiva (formerly GE Healthcare Life Sciences) and show positive initial performance data.
The SARS-CoV-2 pandemic has placed unprecedented pressure on research and diagnostic laboratories to process more samples more quickly. INTEGRA Biosciences offers a range of pipetting systems designed to speed up PCR-based screening workflows.
Ploughshare Innovations, a Defence Science and Technology Laboratory (Dstl) spin-out firm, has funded the development of a revolutionary test that has the potential to predict whether coronavirus patients will develop sepsis before symptoms appear.
Bio-Rad provides a wide range of products for use in the support of COVID-19 diagnosis and confirmation, and offers a suite of molecular testing tools including Droplet Digital PCR (ddPCR) systems and the SARS-CoV-2 ddPCR test kit.
Infectivity assays carried out by the Avacta Group in collaboration with the Centre for Virus Research at the University of Glasgow show that the company’s Affimer reagents prevent infection of human cells by a SARS-CoV-2 model virus.
A Danish pipetting robot is automating coronavirus testing processes in European hospitals. The robot, called flowbot ONE, significantly reduces the time it takes for laboratories to produce results for patients potentially infected with SARS-CoV-2.